A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)

Trial Profile

A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2014

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 14 Apr 2014 Results of this trial will be presented at the American Thoracic Society meeting, according to a Cytos Biotechnology media release.
    • 14 Apr 2014 Status changed from active, no longer recruiting to discontinued, as reported by a Cytos Biotechnology media release.
    • 14 Apr 2014 Primary endpoint 'Significant reduction in Asthma-Control-Questionnaire score with CYT 003 vs placebo at week 12' has not been met, as reported by a Cytos Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top